Delivery Order SPE2DB20D1100-SPE2DB25FB8Z2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $10,185.62. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is expected to be completed by November 19, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,604.51. This is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, executed under a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,904.42. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,929.64 with a firm fixed price structure. The order is non-competitive, non-set-aside delivery order with an ultimate completion date of November 4, 2025. This award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999.9 billion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,406.00. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside, competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $6,387.57. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 5, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,078.89 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,686.96. This firm fixed-price delivery order is scheduled for ultimate completion on April 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded through standard...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FB8Z2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $3,183.70. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by April 24, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a broad range of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This NovoLog insulin order reflects the company's role as a prime vendor supporting military healthcare programs worldwide through the DLA's pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 4/23/25 |